AHA 2020 - Device Treatment Options for Heart Failure: Appropriate Patient Selection & Identification

381 views
November 20, 2020

In this video, Dr. Singh discusses device treatment options available to heart failure patients that remain sympotomatic despite being on guideline directed medical therapy.  CCM® therapy is discussed and the indications for use are outlined including:   NYHA Class III,  EF 25 - 45%, that remain symptomatic despite being treated with Guideline Directed Medical Therapy and that are NOT indicated for Cardiac Resynchronization Therapy.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
0 Comments
Login to view comments. Click here to Login